The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity
-
Published:2019-12-06
Issue:3
Volume:20
Page:328-338
-
ISSN:1530-7905
-
Container-title:Cardiovascular Toxicology
-
language:en
-
Short-container-title:Cardiovasc Toxicol
Author:
Mattila Minttu, Söderström Mirva, Ailanen Liisa, Savontaus EriikaORCID, Savontaus Mikko
Abstract
AbstractDoxorubicin is a potent anticancer drug with cardiotoxicity hampering its use. Neuropeptide Y (NPY) is the most abundant neuropeptide in the heart and a co-transmitter of the sympathetic nervous system that plays a role in cardiac diseases. The aim of this work was to study the impact of NPY on doxorubicin-induced cardiotoxicity. Transgenic mice overexpressing NPY in noradrenergic neurons (NPY-OEDβH) and wild-type mice were treated with a single dose of doxorubicin. Doxorubicin caused cardiotoxicity in both genotypes as demonstrated by decreased weight gain, tendency to reduced ejection fraction, and changes in the expression of several genes relevant to cardiac pathology. Doxorubicin resulted in a tendency to lower ejection fraction in NPY-OEDβH mice more than in wild-type mice. In addition, gain in the whole body lean mass gain was decreased only in NPY-OEDβH mice, suggesting a more severe impact of doxorubicin in this genotype. The effects of doxorubicin on genes expressed in the heart were similar between NPY-OEDβH and wild-type mice. The results demonstrate that doxorubicin at a relatively low dose caused significant cardiotoxicity. There were differences between NPY-OEDβH and wild-type mice in their responses to doxorubicin that suggest NPY to increase susceptibility to cardiotoxicity. This may point to the therapeutic implications as suggested for NPY system in other cardiovascular diseases.
Funder
Varsinais-Suomen Rahasto Turun Yliopisto Sydäntutkimussäätiö Orionin Tutkimussäätiö Aarne Koskelon Säätiö Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimussäätiö
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference62 articles.
1. Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. (2010). Doxorubicin cardiomyopathy. Cardiology,115, 155–162. 2. Ghigo, A., Li, M., & Hirsch, E. (2016). New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochimica et Biophysica Acta,1863, 1916–1925. 3. Tong, J., Ganguly, P. K., & Singal, P. K. (1991). Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. American Journal of Physiology,260, H909–H916. 4. Bartoli, C., Brittian, K., Giridharan, G., Koenig, S., Hamid, T., & Prabhu, S. (2011). Bovine model of doxorubicin-induced cardiomyopathy. Journal of Biomedicine and Biotechnology,2011, 758736–758736. 5. Hjalmarson, A., Waagstein, F. (1994). The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs, 47(Suppl 4), 31–9; discussion 39
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|